Production of Vaccines with Special Reference to Rubella Vaccine RA 27/3 Strain in WI 38 Cells

  • A. J. Beale
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 31)


When a disease is sufficiently serious to warrant prevention and a vaccine has been seen to be technically possible, it is necessary to devise methods of preparation and testing that minimize the dangers inherent in large scale manufacture. It is one thing for an investigator to prepare a few doses of vaccine with loving care in his laboratory to demonstrate its potential usefulness and quite another to prepare millions of doses of a safe and effective vaccine, year by year. The methods for controlling industrial production of vaccines have been developed slowly through the years and are still being developed. There have been some spectacular errors, some of which are listed in Table 1, but on the whole the record has been one of solid progress. Indeed the very success of vaccination programs has led to new problems for public health officials. Thus the control of smallpox, largely by vaccine, has brought a new balance of risks of vaccination against the risks of the disease. Because the risks of complications of vaccination now outweigh the risks of smallpox, many countries are abandoning routine smallpox vaccine, and as other diseases come under control the use of other vaccines may be brought into question.


Influenza Vaccine Rubella Vaccine Large Scale Manufacture Yellow Fever Vaccine Infectious Bovine Rhinotracheitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Plenum Press, New York 1972

Authors and Affiliations

  • A. J. Beale
    • 1
  1. 1.Biological DivisionThe Wellcome Research LaboratoriesBeckenhamU.K.

Personalised recommendations